Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Will probably drop price a little due to a combination of MMs playing clever games and people making knee jerk reactions without proper research.
Once people realise the facts about the availability of the Moderna vaccine should recover quickly.
There will come a time (regardless of covid tests) when investors realise that all of these comparatively small revenue streams are slowly adding up to a substantial and sustained income for avacta.
The therapeutic and diagnostic works are gradually realising the incredible potential of Affimers.
Covid diagnostics are the icing on and already amazing cake. A few more RNS like todays alongside LFT and BAMS and the value here could surprise us all.
Agreed. This is done and dusted at 35p now. Fully expect vote to go through on the 14th. Should all be paid up before Easter.
No.
Agreed, the goverment bought a shed load of innova tests and need to use them up. Hence the contract to fly the latest and hopefully last batch over.
I have no doubt avactas big deals are coming however this is just a little too soon.
I do think we will be bidding for part to the 912m lfd tender though. That is in our timescale.
Also convinced BAMS could be massive.
Not talked about Testing? Testing had been some of the major recent headlines.
None of the major vaccine manufactures have been able to say for sure how long their vaccines will last for, they have mentioned anything from 3-12 months and you think their will be no more need for testing.
Why do people only mention UK needs. It will probably be our smallest market in the the long term. The world is a big old place, absolutely no chance it is going to reach the stage where no tests are needed anytime soon.
Many millions of flu tests are still performed world wide each year despite a vaccine being around for decades.
I think its safe to say any company producing tests with a decent standard of s/s will sell every test they make for the foreseeable. BAMS(if its up to standard) because its cheaper and quicker and LFD(validation results being good enough) because its competitors aren't up to much and an LFD with decent S/S will make a huge difference to the way events/travel/educational institutions etc can be managed.
Just waiting for validation results. If they are good enough I have no doubt we will sell every test we can get made, both BAMS and LFD.
Haven't seen many people disagree with the fact that timelines have slipped and that AS has made some very questionable decisions.
However suggestions there will be no market for tests and we have missed the boat are laughable. People suggesting the covid crisis will be over anytime soon are deluded and bound to be called out.
You should see the AVCT board. Overun with trolls. This is sweet bliss.
I would suggest it is certainly a better use of anyones time to read about all of avactas ongoing projects on their website than read this board currently.
All the latest updates with actual real information.
From May. Get a grip. Why are you here? I can guarantee everyone on this board would be happy to sacrifice all their shares in return for a cure for cancer developed by any company. I and I'm sure all of you on this board have had my fair share of tragedy because if it. So go deramp somewhere else.
Old news, they have been trying to flog that antibody test for some time.
They are very clever in the way they word the description of the test, implying it is just as effective as an antigen test.
The fact is it is just an antibody test.
If you have covid but have not yet developed antibodies it is useless.
I believe the AA was asset stripped to the bone the last time it was private equity owned by centrica.
Not sure it has much left except a very good insurance business.
But make no mistake its very unlikely this buyout will be good for the company. The new owners will have an angle.
Good to see BAMS too though. I think for a long time it was seen as a second fiddle to LFD but I wouldn't be surprised if the lower cost per test and potentially better performance than PCR turns into worldwide revenues that that surprise us all.